Onychomycosis treatment market seen hitting $5.8 billion by 2032

Persistence Market Research says the global onychomycosis treatment market will grow from $4.1 billion in 2025 to $5.8 billion by 2032, driven by rising fungal nail infections, earlier diagnosis and broader access to treatment. Oral antifungal drugs remain the biggest segment, while North America stays the largest regional market.

Why it matters: - Fungal nail infections are becoming a bigger treatment need among aging adults, people with diabetes and patients with weakened immune systems. - Faster diagnosis and more treatment options could push more patients into care earlier, which can reduce complications and improve outcomes. - The market outlook signals ongoing demand for dermatology drugs, procedures and clinic services.

What happened: - Persistence Market Research valued the global onychomycosis treatment market at US$ 4.1 billion in 2025. - The market is projected to reach US$ 5.8 billion by 2032. - The forecast implies a 5.1% compound annual growth rate from 2025 to 2032. - The report points to rising awareness of nail health, early diagnosis and advanced treatment options as demand drivers.

The details: - Oral antifungal therapies remain the leading treatment segment because they are effective for moderate and severe infections. - Topical therapies continue to serve patients with mild infections and those seeking non-invasive care. - Laser therapy is gaining attention as a drug-free alternative. - Hospitals and dermatology clinics remain the main end users because they offer specialized diagnosis and treatment. - Retail pharmacies and online pharmacies are expanding access and convenience for patients. - Digital health services, teleconsultation and easier prescription access are making treatment more reachable in some markets. - North America is expected to stay the leading regional market. - Europe remains a significant market. - Asia Pacific is emerging as a faster-growing region. - The report identifies major players including Bausch Health Companies, Pfizer, Novartis, Galderma, Bayer, GlaxoSmithKline and Sanofi. - The source includes a free sample report, report customization and a full report purchase page.

Between the lines: - The growth story is less about one breakthrough drug and more about steady demand across multiple treatment formats. - The report suggests patients are getting diagnosed and treated earlier, which favors both prescription therapies and clinic-based care. - North America’s lead reflects stronger infrastructure, awareness and reimbursement, while Asia Pacific’s rise points to expanding healthcare access.

What's next: - Investment in dermatology research is likely to continue as companies look for better formulations with shorter treatment times and fewer side effects. - Combination therapies and laser-based options may gain more clinical traction if they keep showing value for difficult cases. - Expanding digital care and pharmacy access could widen treatment adoption in emerging markets. - Strategic partnerships and broader distribution networks are likely to shape competition over the forecast period.